Flex Pharma Company Profile (NASDAQ:FLKS)

About Flex Pharma (NASDAQ:FLKS)

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FLKS
  • CUSIP: N/A
  • Web: www.flex-pharma.com
Capitalization:
  • Market Cap: $58.08 million
  • Outstanding Shares: 17,285,000
Average Prices:
  • 50 Day Moving Avg: $3.43
  • 200 Day Moving Avg: $3.43
  • 52 Week Range: $3.01 - $8.43
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.43
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.48 million
  • Price / Sales: 39.24
  • Book Value: $2.58 per share
  • Price / Book: 1.30
Profitability:
  • EBITDA: ($35,580,000.00)
  • Net Margins: -2,410.97%
  • Return on Equity: -64.15%
  • Return on Assets: -59.78%
Debt:
  • Current Ratio: 9.75%
  • Quick Ratio: 9.62%
Misc:
  • Average Volume: 24,864 shs.
  • Beta: 3.3
  • Short Ratio: 1.22
 

Frequently Asked Questions for Flex Pharma (NASDAQ:FLKS)

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma, Inc. (NASDAQ:FLKS) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.12. The business earned $0.34 million during the quarter, compared to the consensus estimate of $0.46 million. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. View Flex Pharma's Earnings History.

When will Flex Pharma make its next earnings announcement?

Flex Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Flex Pharma.

Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?

5 brokerages have issued 12-month price objectives for Flex Pharma's shares. Their forecasts range from $8.00 to $14.00. On average, they expect Flex Pharma's stock price to reach $11.00 in the next year. View Analyst Ratings for Flex Pharma.

What are analysts saying about Flex Pharma stock?

Here are some recent quotes from research analysts about Flex Pharma stock:

  • 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (10/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "Phase II COMMEND trial of FLX-787 is expected to have data in 2018 in ALS." (9/25/2017)

Who are some of Flex Pharma's key competitors?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:

  • Christoph H. Westphal M.D. Ph.D., Chairman of the Board
  • William K. McVicar Ph.D., President, Chief Executive Officer, Director
  • John McCabe, Chief Financial Officer, Treasurer
  • Kathie Lindemann, Chief Operating Officer
  • Jennifer Cermak Ph.D., Vice President - Research & Development
  • Robert Hadfield Ph.D., General Counsel, Secretary
  • Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications
  • Thomas C. Wessel M.D. Ph.D., Chief Medical Officer
  • Jeffrey D. Capello, Director
  • Roderick Mackinnon M.D, Director

When did Flex Pharma IPO?

(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

How do I buy Flex Pharma stock?

Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flex Pharma's stock price today?

One share of Flex Pharma stock can currently be purchased for approximately $3.36.


MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $11.00 (227.38% upside)
Consensus Price Target History for Flex Pharma (NASDAQ:FLKS)
Price Target History for Flex Pharma (NASDAQ:FLKS)
Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingHold$10.00MediumView Rating Details
9/7/2017Roth CapitalInitiated CoverageBuy$14.00LowView Rating Details
5/4/2017Jefferies Group LLCLower Price TargetBuy$9.00 -> $8.00HighView Rating Details
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$12.00LowView Rating Details
11/3/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016HC WainwrightReiterated RatingBuy$40.00N/AView Rating Details
(Data available from 10/16/2015 forward)

Earnings

Earnings History for Flex Pharma (NASDAQ:FLKS)
Earnings by Quarter for Flex Pharma (NASDAQ:FLKS)
Earnings History by Quarter for Flex Pharma (NASDAQ FLKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.60)N/AView Earnings Details
8/2/2017Q2 2017($0.63)($0.51)$0.46 million$0.34 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.62)($0.49)$0.38 million$0.24 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.84)($0.48)$0.09 million$0.30 millionViewListenView Earnings Details
11/2/2016Q316($0.72)($0.65)$0.15 million$0.60 millionViewListenView Earnings Details
8/3/2016Q216($0.67)($0.71)$0.01 million$0.11 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.32)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
2017 EPS Consensus Estimate: ($2.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.46)($0.46)($0.46)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Flex Pharma (NASDAQ:FLKS)
Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 27.74%
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)
Institutional Ownership by Quarter for Flex Pharma (NASDAQ:FLKS)
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2016Christoph H WestphalInsiderBuy7,000$7.31$51,170.00View SEC Filing  
11/7/2016Christoph H WestphalInsiderBuy8,870$5.70$50,559.00View SEC Filing  
11/7/2016John P MccabeVPBuy1,650$6.01$9,916.50View SEC Filing  
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Flex Pharma (NASDAQ:FLKS)
Latest Headlines for Flex Pharma (NASDAQ:FLKS)
Source:
DateHeadline
finance.yahoo.com logoFlex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
finance.yahoo.com - October 16 at 7:04 PM
americanbankingnews.com logoFlex Pharma, Inc. (FLKS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 11:06 AM
americanbankingnews.com logo Analysts Expect Flex Pharma, Inc. (FLKS) Will Announce Quarterly Sales of $470,000.00
www.americanbankingnews.com - October 4 at 5:40 PM
americanbankingnews.com logoHead to Head Comparison: Flex Pharma (FLKS) vs. Axovant Sciences (AXON)
www.americanbankingnews.com - October 1 at 6:24 AM
americanbankingnews.com logoFlex Pharma, Inc. (FLKS) Receives Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 9:14 PM
americanbankingnews.com logoFlex Pharma, Inc. (FLKS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 11:02 AM
americanbankingnews.com logoFlex Pharma, Inc. (FLKS) Coverage Initiated at Roth Capital
www.americanbankingnews.com - September 7 at 8:58 PM
finance.yahoo.com logoFlex Pharma Presenting at Upcoming Investor Conferences in September 2017
finance.yahoo.com - September 6 at 6:35 PM
finance.yahoo.com logoETFs with exposure to Flex Pharma, Inc. : September 1, 2017
finance.yahoo.com - September 2 at 12:00 AM
americanbankingnews.com logo$500,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - August 27 at 4:46 AM
finance.yahoo.com logoFlex Pharma, Inc. :FLKS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 8:06 PM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 10 at 9:10 AM
americanbankingnews.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Expected to Post Quarterly Sales of $500,000.00
www.americanbankingnews.com - August 9 at 7:24 AM
americanbankingnews.com logoJefferies Group Comments on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 7 at 7:46 AM
finance.yahoo.com logoEdited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT
finance.yahoo.com - August 3 at 4:01 PM
americanbankingnews.com logoFlex Pharma, Inc. (FLKS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - August 3 at 2:52 PM
finance.yahoo.com logoInvestor Network: Flex Pharma, Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 7:37 PM
finance.yahoo.com logoFlex Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 7:37 PM
finance.yahoo.com logoFlex Pharma reports 2Q loss
finance.yahoo.com - August 2 at 7:37 PM
finance.yahoo.com logoFlex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
finance.yahoo.com - August 1 at 7:17 PM
finance.yahoo.com logoFlex Pharma Names William McVicar President and Chief Executive Officer
finance.yahoo.com - July 31 at 6:25 PM
americanbankingnews.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM
finance.yahoo.com logoCorporate News Blog - FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 27 at 7:14 PM
finance.yahoo.com logoFlex Pharma to Report Second Quarter 2017 Results on August 2, 2017
finance.yahoo.com - July 27 at 12:17 AM
finance.yahoo.com logoFDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 25 at 6:57 PM
americanbankingnews.com logo$460,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - July 20 at 1:46 PM
americanbankingnews.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Short Interest Down 56.7% in June
www.americanbankingnews.com - July 16 at 7:08 AM
americanbankingnews.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 11:24 AM
bizjournals.com logoHOTSHOT Partners With IRONMAN To Help Athletes Prevent Muscle Cramping
www.bizjournals.com - June 29 at 4:21 AM
streetinsider.com logoFlex Pharma (FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth by Inherited Neuropathies Consortium
www.streetinsider.com - June 2 at 6:33 PM
streetinsider.com logoFlex Pharma Announce Presentation of Human Efficacy Data on FLX-787 at American Academy of Neurology Annual Meeting on 4/27
www.streetinsider.com - April 19 at 5:07 PM
seekingalpha.com logoFlex Pharma's (FLKS) CEO Christoph Westphal on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 4:04 AM
us.rd.yahoo.com logoFlex Pharma Reports Year End 2016 Financial Results
us.rd.yahoo.com - March 8 at 6:01 PM
biz.yahoo.com logoQ4 2016 Flex Pharma Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 8 at 6:01 PM
biz.yahoo.com logoFLEX PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 8 at 6:01 PM
streetinsider.com logoFlex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in Severe Neurological Diseases
www.streetinsider.com - January 24 at 10:55 PM
streetinsider.com logoFlex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in ... - StreetInsider.com
www.streetinsider.com - January 24 at 5:54 PM
streetinsider.com logoFlex Pharma (FLKS) Discloses John McCabe Promoted to CFO - StreetInsider.com
www.streetinsider.com - December 16 at 5:47 PM
streetinsider.com logoFlex Pharma (FLKS) Discloses John McCabe Promoted to CFO
www.streetinsider.com - December 15 at 5:49 PM
biz.yahoo.com logoFLEX PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial
biz.yahoo.com - December 15 at 5:49 PM

Social

Chart

Flex Pharma (FLKS) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.